Future studies may be needed to test the potency and safety of CasRx-based anti-KrasG12D using other murine G12D Kras pancreatic cancer cell lines or in an immunocompetent mice such as the KPC mice 31, 32. This evidence concerns the gene KRAS and familial pancreatic carcinoma.